Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy.
Theodoridou
Athina
A
Rheumatology Unit, 1st Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece.
Kartsios
Charalambos
C
Yiannaki
Efthalia
E
Markala
Dimitra
D
Settas
Lucas
L
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D016130:Immunophenotyping; D016131:Lymphocyte Subsets / Q000187:drug effects; D008218:Lymphocytosis / Q000139:chemically induced* / Q000145:classification; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced*; D013601:T-Lymphocytes / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab